참고문헌
- Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:762-766. https://doi.org/10.1001/archotol.132.7.762
- Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993;85:95- 111. https://doi.org/10.1093/jnci/85.2.95
- Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994; 86:265-272. https://doi.org/10.1093/jnci/86.4.265
- Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949- 955. https://doi.org/10.1016/S0140-6736(00)90011-4
- Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer(MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14. https://doi.org/10.1016/j.radonc.2009.04.014
- Fujii M, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, et al. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn J Clin Oncol. 2010;40:214-221. https://doi.org/10.1093/jjco/hyp153
- Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer. 2000;83: 1594-1598. https://doi.org/10.1054/bjoc.2000.1512
- Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985;55:1123-1128. https://doi.org/10.1002/1097-0142(19850301)55:5<1123::AID-CNCR2820550530>3.0.CO;2-8
- Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med. 2008;22:709-716.
- Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Late phase II study of S-1 in patients with advanced head and neck cancer]. Gan To Kagaku Ryoho. 2001;28:1381-1390.
- Choi YJ, Chung JS, Shin HJ, Cho GJ, Wang SG, Lee BJ, et al. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. J Laryngol Otol. 2008;122:848-853.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. https://doi.org/10.1093/jnci/92.3.205
- D'Ambrosio DJ, Li T, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does treatment duration affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys. 2008;72:1402-1407. https://doi.org/10.1016/j.ijrobp.2008.03.011
- Chan AT, Teo PM, Johnson PJ. Nasopharyngeal cancer. Cancer Treat Res. 2003;114:275-293.
- Lee JL, Kang HJ, Kang YK, Ryu MH, Chang HM, Kim TW, et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol. 2008;61:837-845. https://doi.org/10.1007/s00280-007-0541-5
- Yoon DH, Kim SB. S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer? Expert Rev Anticancer Ther. 2010;10:659-662. https://doi.org/10.1586/era.10.45
- Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-8645. https://doi.org/10.1200/JCO.2004.00.1990
- Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357:1705-1715. https://doi.org/10.1056/NEJMoa070956
- Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695- 1704. https://doi.org/10.1056/NEJMoa071028
- Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia Giron C, Irigoyen A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol. 2009; 27:15s(suppl; abstr 6009). https://doi.org/10.1200/JCO.2008.21.7695